Affordable Access

Access to the full text

Patientenauswahl für die Immun-Checkpoint-Therapie bei fortgeschrittenem nicht kleinzelligem Lungenkarzinom: Bedeutungen für die klinische Praxis

Authors
  • Schütte, Wolfgang
  • Möller, Miriam
Type
Published Article
Journal
Karger Kompass Onkologie
Publisher
S. Karger GmbH
Publication Date
May 27, 2019
Volume
6
Issue
2
Pages
104–105
Identifiers
DOI: 10.1159/000500528
Source
Karger
Keywords
License
Green
External links

Abstract

Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.

Report this publication

Statistics

Seen <100 times